Nisa Investment Advisors’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $147K | Buy |
736
+6
| +0.8% | +$1.19K | ﹤0.01% | 1307 |
|
|
2025
Q4 | $138K | Sell |
730
-68
| -9% | -$13.1K | ﹤0.01% | 1330 |
|
|
2025
Q3 | $141K | Buy |
798
+24
| +3% | +$3.57K | ﹤0.01% | 1341 |
|
|
2025
Q2 | $88K | Sell |
774
-16
| -2% | -$1.71K | ﹤0.01% | 1439 |
|
|
2025
Q1 | $83.1K | Sell |
790
-3
| -0.4% | -$339 | ﹤0.01% | 1448 |
|
|
2024
Q4 | $85K | Buy |
793
+35
| +5% | +$3.96K | ﹤0.01% | 1519 |
|
|
2024
Q3 | $75.9K | Buy |
758
+2
| +0.3% | +$201 | ﹤0.01% | 1523 |
|
|
2024
Q2 | $63.7K | Buy |
756
+15
| +2% | +$1.19K | ﹤0.01% | 1594 |
|
|
2024
Q1 | $54.2K | Buy |
741
+15
| +2% | +$1.11K | ﹤0.01% | 1632 |
|
|
2023
Q4 | $51.9K | Buy |
726
+10
| +1% | +$590 | ﹤0.01% | 1628 |
|
|
2023
Q3 | $42.9K | Sell |
716
-8
| -1% | -$527 | ﹤0.01% | 1769 |
|
|
2023
Q2 | $52.2K | Buy |
724
+60
| +9% | +$4.5K | ﹤0.01% | 1741 |
|
|
2023
Q1 | $49K | Hold |
664
| – | – | ﹤0.01% | 1725 |
|
|
2022
Q4 | $44K | Sell |
664
-400
| -38% | -$26K | ﹤0.01% | 1819 |
|
|
2022
Q3 | $58K | Buy |
1,064
+19
| +2% | +$1.12K | ﹤0.01% | 1692 |
|
|
2022
Q2 | $58K | Sell |
1,045
-160
| -13% | -$9.08K | ﹤0.01% | 1683 |
|
|
2022
Q1 | $85K | Buy |
1,205
+59
| +5% | +$4.28K | ﹤0.01% | 1677 |
|
|
2021
Q4 | $89K | Hold |
1,146
| – | – | ﹤0.01% | 1561 |
|
|
2021
Q3 | $100 | Hold |
1,146
| – | – | ﹤0.01% | 1703 |
|
|
2021
Q2 | $94 | Hold |
1,146
| – | – | ﹤0.01% | 1724 |
|
|
2021
Q1 | $109 | Buy |
1,146
+320
| +39% | +$30.3K | ﹤0.01% | 1717 |
|
|
2020
Q4 | $51K | Sell |
826
-961
| -54% | -$54.8K | ﹤0.01% | 1988 |
|
|
2020
Q3 | $106K | Buy |
1,787
+865
| +94% | +$59K | ﹤0.01% | 1528 |
|
|
2020
Q2 | $64K | Sell |
922
-1,531
| -62% | -$97.1K | ﹤0.01% | 1541 |
|
|
2020
Q1 | $111K | Buy |
2,453
+433
| +21% | +$24.5K | ﹤0.01% | 1338 |
|
|
2019
Q4 | $131K | Buy |
2,020
+321
| +19% | +$21.5K | ﹤0.01% | 1393 |
|
|
2019
Q3 | $106K | Buy |
1,699
+1,539
| +962% | +$96.6K | ﹤0.01% | 1449 |
|
|
2019
Q2 | $11K | Hold |
160
| – | – | ﹤0.01% | 1732 |
|
|
2019
Q1 | $13K | Hold |
160
| – | – | ﹤0.01% | 1688 |
|
|
2018
Q4 | $14K | Sell |
160
-12,412
| -99% | -$1.32M | ﹤0.01% | 1566 |
|
|
2018
Q3 | $2.15M | Buy |
12,572
+12,332
| +5,138% | +$1.86M | 0.02% | 631 |
|
|
2018
Q2 | $31K | Buy |
240
+80
| +50% | +$8.93K | ﹤0.01% | 1502 |
|
|
2018
Q1 | $17K | Sell |
160
-80
| -33% | -$7.91K | ﹤0.01% | 1503 |
|
|
2017
Q4 | $21K | Hold |
240
| – | – | ﹤0.01% | 1537 |
|
|
2017
Q3 | $20K | Hold |
240
| – | – | ﹤0.01% | 1528 |
|
|
2017
Q2 | $18K | Hold |
240
| – | – | ﹤0.01% | 1518 |
|
|
2017
Q1 | $16K | Hold |
240
| – | – | ﹤0.01% | 1552 |
|
|
2016
Q4 | $15K | Sell |
240
-401
| -63% | -$25.3K | ﹤0.01% | 1720 |
|
|
2016
Q3 | $41K | Hold |
641
| – | – | ﹤0.01% | 1427 |
|
|
2016
Q2 | $48K | Hold |
641
| – | – | ﹤0.01% | 1403 |
|
|
2016
Q1 | $43K | Buy |
+641
| New | +$39K | ﹤0.01% | 1409 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
Nisa Investment Advisors's LGND Position: Q1 2026 in Review
Nisa Investment Advisors increased its Ligand Pharmaceuticals (LGND) stake by 0.82% in Q1 2026, buying an estimated $1.19K and bringing the position to 736 shares worth $147K. The position accounts for ﹤0.01% of the portfolio, ranked #1307.
Nisa Investment Advisors first reported a position in LGND in Q1 2016 and has held it in 41 quarters since. The position peaked at $2.15M in Q3 2018. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Nisa Investment Advisors held 736 shares of Ligand Pharmaceuticals worth $147K as of Q1 2026.
- Nisa Investment Advisors bought 6 Ligand Pharmaceuticals shares in Q1 2026, an estimated $1.19K.
- Ligand Pharmaceuticals made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q1 2026, its #1307 holding.
- Nisa Investment Advisors first reported a position in Ligand Pharmaceuticals in Q1 2016 and has held it in 41 quarters since.
- Nisa Investment Advisors's Ligand Pharmaceuticals position peaked at $2.15M in Q3 2018.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Nisa Investment Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.